EDITOR
Early availability of the consent document permitting subjects to read it ahead of time, so that they can reflect and formulate questions prior to meeting for IC signature. Trained staff, fluent in the patients' language, who are available at the time of IC document signing AND afterwards for answering questions. Description of sample collection. Is the same IC document used for the drug trial and for the pharmacogenomic study? Nature of association with drug trial: can one participate in the drug trial without donating DNA for the related pharmacogenomic study? Archiving DNA. Creation and immortalization of cell lines. Description of sample storage. Procedures for assurance of confidentiality. Description of the level of sample anonymity (samples can be identified, coded, doublecoded/de-identified, anonymized, or anonymous). Availability of procedures for withdrawing subjects' data and samples if they so desire at a later date and a clear description of the limitation to this approach, including timeline (eg, once samples are anonymized it is no longer possible to retrieve them; once data are pooled, analyzed and presented or published it is no longer possible to retrieve them). Scientific use of the sample: can the sample be used only for the testing of a specific target/hypothesis, or can it be used for any type of genetic or pharmacogenetic research? Ownership of the sample. Commercial uses of the sample (intellectual property). Distribution of genetic material to secondary users (even the parties are not yet defined). Criteria for the distribution of genetic material to secondary users. Location of secondary users (national vs international). Type of primary or secondary users (academic, not-for-profit, for profit/commercial). Compensation to subjects, if any. Personal vs society benefits. Options for contacting subjects in the future (possible only for non-anonymized/anonymous samples). Post-testing options for communication and sharing of genetic results with subjects. Sharing of unintended genetic results, particularly if directly relevant to medical care, with subjects, family members, or health care providers.
